InMed Pharmaceuticals Reports Third Quarter Fiscal 2022

Expands rare cannabinoid portfolio with the addition of CBT and CBDVStrengthens IP with publication of a patent application for novel cannabinoid...

Related Keywords

United States ,United Kingdom ,Vancouver ,British Columbia ,Canada ,America ,British ,Jerryp Griffin ,Mauro Maccarrone ,Jerry Griffin ,Erica Adams ,Bryan Baldasare ,Department Of Biotechnological ,Hilltop Companies ,Company Phase ,Company Nasdaq ,Radicle Science Energy ,Drug Administration ,Clinical Sciences ,Arthur Andersen ,University Of Cincinnati ,Development Programs ,Business Administration ,Inmed Pharmaceuticals Inc ,Med Pharmaceuticals ,Inmed President ,Radicle Science ,Epidermolysis Bullosa ,Investigational New Drug ,Chemistry Manufacturing ,North America ,Applied Clinical Sciences ,Meridian Bioscience ,Chief Financial Officer ,Operational Highlights ,Nasdaq Capital ,Condensed Consolidated Interim Balance Sheets ,Nasdaq Inm ,Nmed Pharmaceuticals Inc ,